Tesamorelin: The GHRH Analog for GH-Axis Research

Tesamorelin is the full-length answer to a design problem: native growth-hormone-releasing hormone (GHRH) is destroyed by enzymes within minutes. Tesamorelin keeps the complete 44-amino-acid sequence and modifies it to survive long enough to be a useful research compound.

The molecule

Tesamorelin is a 44-amino-acid analog of GHRH 1-44 (C₂₂₁H₃₆₆N₇₂O₆₇S, ≈ 5136 g/mol). Where native GHRH is rapidly degraded, Tesamorelin’s modifications protect it against DPP-IV and other peptidases — the same stability logic seen across GHRH-pathway research peptides.

What the research looks at

Tesamorelin research clusters around the GH axis:

• Growth-hormone secretion — direct GHRH-receptor agonism studies in pituitary and metabolic models
• Visceral-adipose and metabolic modeling — the most distinctive thread, examining GH-driven changes in body composition
• GHRH-receptor pharmacology — binding and signaling studies for the GHRH-R

A landmark clinical reference is Falutz et al. (JAMA, 2010) on tesamorelin’s effects on visceral fat.

How it fits the GHRH family

Tesamorelin sits at one end of the GHRH-analog spectrum: the full 44-mer. Sermorelin is the 1-29 fragment, and CJC-1295 No DAC (Mod GRF 1-29) is a tetrasubstituted variant — comparing them is a useful way to study how length and substitutions change stability and signaling.

Handling notes

Lyophilized, reconstitute with bacteriostatic water; the reconstitution calculator handles the math. Store at −20°C lyophilized.

See Tesamorelin for CAS, purity and full specifications.

For laboratory research use only. Not medical advice.